J Korean Med Assoc.  2012 Feb;55(2):146-152. 10.5124/jkma.2012.55.2.146.

Updates on the prevention and treatment of AIDS

• Choi JY
• Kim JM

• KMID: 2192663
• DOI: http://doi.org/10.5124/jkma.2012.55.2.146

Abstract

June 5, 2011, marked the 30th year since the first cases of acquired immunodeficiency syndrome (AIDS) were reported. From just five cases in the initial publication, AIDS has grown into a global pandemic that has resulted in the deaths of more than 33 million people around the world. There have been many successful stories of human immunodeficiency virus (HIV) treatment and prevention during the past 3 decades of the AIDS epidemic. Among them, HIV chemotherapy has been a major medical accomplishment and has dramatically reduced the morbidity and mortality of those with access to care. The combination of prevention and treatment has substantially decreased the spread of the disease and dramatically increased life expectancy among treated patients. Ongoing studies on curing HIV infections are providing us with hopeful perspectives for eradicating this huge epidemic. We must attain the sustainability of economic resources in order to ensure the continuation of the advances that have been achieved and provide new perspectives on future challenges.

Keyword

HIV; Acquired immunodeficiency syndrome; Antiretroviral therapy; Prevention & control

MeSH Terms

Acquired Immunodeficiency Syndrome
Dietary Sucrose
HIV
HIV Infections
Humans
Life Expectancy
Pandemics
Publications
Dietary Sucrose

Reference

1. Centers for Disease Control and Prevention (CDC). Pneumocystis pneumonia--Los Angeles. 1981. MMWR Morb Mortal Wkly Rep. 1996. 45:729–733.

2. Barre-Sinoussi F, Chermann JC, Rey F, Nugeyre MT, Chamaret S, Gruest J, Dauguet C, Axler-Blin C, Vezinet-Brun F, Rouzioux C, Rozenbaum W, Montagnier L. Isolation of a T-lymphotropic retrovirus from a patient at risk for acquired immune deficiency syndrome (AIDS). Science. 1983. 220:868–871.

3. Luciw PA, Potter SJ, Steimer K, Dina D, Levy JA. Molecular cloning of AIDS-associated retrovirus. Nature. 1984-1985. 312:760–763.

4. Kim JM, Cho GJ, Hong SK, Chang KH, Chung JS, Choi YH, Song YG, Huh A, Yeom JS, Lee KS, Choi JY. Epidemiology and clinical features of HIV infection/AIDS in Korea. Yonsei Med J. 2003. 44:363–370.

5. Oh MD, Park SW, Kim HB, Kim US, Kim NJ, Choi HJ, Shin DH, Lee JS, Choe K. Spectrum of opportunistic infections and malignancies in patients with human immunodeficiency virus infection in South Korea. Clin Infect Dis. 1999. 29:1524–1528.

6. Hammer SM, Squires KE, Hughes MD, Grimes JM, Demeter LM, Currier JS, Eron JJ Jr, Feinberg JE, Balfour HH Jr, Deyton LR, Chodakewitz JA, Fischl MA. AIDS Clinical Trials Group 320 Study Team. A controlled trial of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus infection and CD4 cell counts of 200 per cubic millimeter or less. N Engl J Med. 1997. 337:725–733.

7. The Korean Society for AIDS. Clinical guidelines for the diagnosis and treatment of HIV/AIDS in HIV-infected Koreans. Infect Chemother. 2011. 43:89–128.

8. Chun TW, Carruth L, Finzi D, Shen X, DiGiuseppe JA, Taylor H, Hermankova M, Chadwick K, Margolick J, Quinn TC, Kuo YH, Brookmeyer R, Zeiger MA, Barditch-Crovo P, Siliciano RF. Quantification of latent tissue reservoirs and total body viral load in HIV-1 infection. Nature. 1997. 387:183–188.

9. Thompson MA, Aberg JA, Cahn P, Montaner JS, Rizzardini G, Telenti A, Gatell JM, Gunthard HF, Hammer SM, Hirsch MS, Jacobsen DM, Reiss P, Richman DD, Volberding PA, Yeni P, Schooley RT. International AIDS Society-USA. Antiretroviral treatment of adult HIV infection: 2010 recommendations of the International AIDS Society-USA panel. JAMA. 2010. 304:321–333.

10. Mellors JW, Munoz A, Giorgi JV, Margolick JB, Tassoni CJ, Gupta P, Kingsley LA, Todd JA, Saah AJ, Detels R, Phair JP, Rinaldo CR Jr. Plasma viral load and CD4+ lymphocytes as prognostic markers of HIV-1 infection. Ann Intern Med. 1997. 126:946–954.

11. Chesney MA. The elusive gold standard. Future perspectives for HIV adherence assessment and intervention. J Acquir Immune Defic Syndr. 2006. 43:Suppl 1. S149–S155.

12. Van Sighem AI, Gras LA, Reiss P, Brinkman K, de Wolf F. ATHENA national observational cohort study. Life expectancy of recently diagnosed asymptomatic HIV-infected patients approaches that of uninfected individuals. AIDS. 2010. 24:1527–1535.

13. Hutter G, Nowak D, Mossner M, Ganepola S, Mussig A, Allers K, Schneider T, Hofmann J, Kucherer C, Blau O, Blau IW, Hofmann WK, Thiel E. Long-term control of HIV by CCR5 Delta32/Delta32 stem-cell transplantation. N Engl J Med. 2009. 360:692–698.

14. Richman DD, Margolis DM, Delaney M, Greene WC, Hazuda D, Pomerantz RJ. The challenge of finding a cure for HIV infection. Science. 2009. 323:1304–1307.

15. Grosskurth H, Gray R, Hayes R, Mabey D, Wawer M. Control of sexually transmitted diseases for HIV-1 prevention: understanding the implications of the Mwanza and Rakai trials. Lancet. 2000. 355:1981–1987.

16. Abdool Karim Q, Abdool Karim SS, Frohlich JA, Grobler AC, Baxter C, Mansoor LE, Kharsany AB, Sibeko S, Mlisana KP, Omar Z, Gengiah TN, Maarschalk S, Arulappan N, Mlotshwa M, Morris L, Taylor D. CAPRISA 004 Trial Group. Effectiveness and safety of tenofovir gel, an antiretroviral microbicide, for the prevention of HIV infection in women. Science. 2010. 329:1168–1174.

17. Cohen MS, Chen YQ, McCauley M, Gamble T, Hosseinipour MC, Kumarasamy N, Hakim JG, Kumwenda J, Grinsztejn B, Pilotto JH, Godbole SV, Mehendale S, Chariyalertsak S, Santos BR, Mayer KH, Hoffman IF, Eshleman SH, Piwowar-Manning E, Wang L, Makhema J, Mills LA, de Bruyn G, Sanne I, Eron J, Gallant J, Havlir D, Swindells S, Ribaudo H, Elharrar V, Burns D, Taha TE, Nielsen-Saines K, Celentano D, Essex M, Fleming TR. HPTN 052 Study Team. Prevention of HIV-1 infection with early antiretroviral therapy. N Engl J Med. 2011. 365:493–505.

18. Connor EM, Sperling RS, Gelber R, Kiselev P, Scott G, O'Sullivan MJ, VanDyke R, Bey M, Shearer W, Jacobson RL. Pediatric AIDS Clinical Trials Group Protocol 076 Study Group. Reduction of maternal-infant transmission of human immunodeficiency virus type 1 with zidovudine treatment. N Engl J Med. 1994. 331:1173–1180.

19. Read JS, Newell MK. Efficacy and safety of cesarean delivery for prevention of mother-to-child transmission of HIV-1. Cochrane Database Syst Rev. 2005. (4):CD005479.

20. Pitisuttithum P, Gilbert P, Gurwith M, Heyward W, Martin M, van Griensven F, Hu D, Tappero JW, Choopanya K. Bangkok Vaccine Evaluation Group. Randomized, double-blind, placebo-controlled efficacy trial of a bivalent recombinant glycoprotein 120 HIV-1 vaccine among injection drug users in Bangkok, Thailand. J Infect Dis. 2006. 194:1661–1671.

21. Flynn NM, Forthal DN, Harro CD, Judson FN, Mayer KH, Para MF. rgp120 HIV Vaccine Study Group. Placebo-controlled phase 3 trial of a recombinant glycoprotein 120 vaccine to prevent HIV-1 infection. J Infect Dis. 2005. 191:654–665.

22. Rerks-Ngarm S, Pitisuttithum P, Nitayaphan S, Kaewkungwal J, Chiu J, Paris R, Premsri N, Namwat C, de Souza M, Adams E, Benenson M, Gurunathan S, Tartaglia J, McNeil JG, Francis DP, Stablein D, Birx DL, Chunsuttiwat S, Khamboonruang C, Thongcharoen P, Robb ML, Michael NL, Kunasol P, Kim JH. MOPH-TAVEG Investigators. Vaccination with ALVAC and AIDSVAX to prevent HIV-1 infection in Thailand. N Engl J Med. 2009. 361:2209–2220.